Skip to main content

Advertisement

Log in

Treatment and survival disparities by ethnicity in New Zealand women with stage I–III breast cancer tumour subtypes

Cancer Causes & Control Aims and scope Submit manuscript

Abstract

Purpose

This study aims to look at the distribution of different subtypes of stage I–III breast cancer in Māori and Pacific versus non-Māori/Pacific women, and to examine cancer outcomes by ethnicity within these different subtypes.

Method

This study included 9,015 women diagnosed with stage I–III breast cancer between June 2000 and May 2013, recorded in the combined Waikato and Auckland Breast Cancer Registers, who had complete data on ER, PR and HER2 status. Five ER/PR/HER2 subtypes were defined. Kaplan–Meier method and Cox proportional hazards model were used to examine ethnic disparities in breast cancer-specific survival.

Results

Of the 9,015 women, 891 were Māori, 548 were Pacific and 7,576 others. Both Māori and Pacific women were less likely to have triple negative breast cancer compared to others (8.6, 8.9 vs. 13.0%). Pacific women were more than twice as likely to have ER−, PR− and HER2+ cancer than Māori and others (14.2 vs. 6.0%, 6.7%). After adjustment for age, year of diagnosis, stage, grade and treatment, the hazard ratios of breast cancer-specific mortality for Māori and Pacific women with ER+, PR+ and HER2− were 1.52 (95% CI 1.06–2.18) and 1.55 (95% CI 1.04–2.31) compared to others, respectively. Māori women with HER2+ cancer were twice more likely to die of their cancer than others.

Conclusions

Outcomes for Māori and Pacific women could be improved by better treatment regimens especially for those with HER2+ breast cancer and for women with ER+, PR+ and HER2− breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Seneviratne SA, Campbell ID, Scott N, Lawrenson RA, Shirley R, Elwood JM (2015) Risk factors associated with mortality from breast cancer in Waikato, New Zealand: a case-control study. Public Health 129(5):549–554. doi:10.1016/j.puhe.2015.02.008

    Article  CAS  PubMed  Google Scholar 

  2. Parise CA, Caggiano V (2014) Breast cancer survival defined by the er/pr/her2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol. doi:10.1155/2014/469251

    PubMed  PubMed Central  Google Scholar 

  3. Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O’Regan R, Torres MA, Meisel JL (2017) Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat 161(2):279–287. doi:10.1007/s10549-016-4059-6

    Article  PubMed  Google Scholar 

  4. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24(36):5652–5657. doi:10.1200/JCO.2006.06.5664

    Article  PubMed  Google Scholar 

  5. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7(1–2):4–13. doi:10.3121/cmr.2009.825

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, Albain KS, André F, Bergh J, Bonnefoi H, Bretel-Morales D, Burstein H, Cardoso F, Castiglione-Gertsch M, Coates AS, Colleoni M, Costa A, Curigliano G, Davidson NE, Leo AD, Ejlertsen B, Forbes JF, Gelber RD, Gnant M, Goldhirsch A, Goodwin P, Goss PE, Harris JR, Hayes DF, Hudis CA, Ingle JN, Jassem J, Jiang Z, Karlsson P, Loibl S, Morrow M, Namer M, Osborne CK, Partridge AH, Penault-Llorca F, Perou CM, Piccart-Gebhart MJ, Pritchard KI, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao ZM, Smith I, Thürlimann B, Toi M, Tutt A, Untch M, Viale G, Watanabe T, Wilcken N, Winer EP, Wood WC (2013) Personalizing the treatment of women with early breast cancer: highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013. Ann Oncol 24(9):2206–2223. doi:10.1093/annonc/mdt303

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329–2334. doi:10.1158/1078-0432.CCR-06-1109

    Article  CAS  PubMed  Google Scholar 

  8. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M (2011) Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365

  9. Seneviratne S, Campbell I, Scott N, Kuper-Hommel M, Kim B, Pillai A, Lawrenson R (2015) Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer outcomes in New Zealand? Breast 24(1):62–67. doi:10.1016/j.breast.2014.11.011

    Article  PubMed  Google Scholar 

  10. Metcalfe S, Evans J, Priest G (2007) PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer. N Z Med J 120:(1256)

    Google Scholar 

  11. New Zealand Herald (2008) National would fund year of Herceptin. http://www.nzherald.co.nz/nz/news/article.cfm?c_id=1&objectid=10524525

  12. Chen L, Li CI (2015) Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status. Cancer Epidemiol Biomarkers Prev 24(11):1666–1672. doi:10.1158/1055-9965.epi-15-0293

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Parise C, Caggiano V (2016) Breast cancer mortality among Asian-American women in California: variation according to ethnicity and tumor subtype. J Breast Cancer 19(2):112–121. doi:10.4048/jbc.2016.19.2.112

    Article  PubMed  PubMed Central  Google Scholar 

  14. National Population Estimates: At 30 June 2016 (2016) http://www.stats.govt.nz/browse_for_stats/population/estimates_and_projections/NationalPopulationEstimates_HOTPAt30Jun16.aspx

  15. Ministry of Health (2015) Tatau Kahukura: Māori health statistics. http://www.health.govt.nz/our-work/populations/maori-health/tatau-kahukura-maori-health-statistics/nga-mana-hauora-tutohu-health-status-indicators/cancer

  16. Earle D (1995) Pacific Islands peoples in Aotearoa/New Zealand: existing and emerging paradigms. Wellington

  17. Campbell I, Scott N, Seneviratne S, Kollias J, Walters D, Taylor C, Roder D (2015) Breast cancer characteristics and survival differences between Maori, Pacific and other New zealand women included in the quality audit program of breast surgeons of Australia and New Zealand. Asian Pac J Cancer Prev 16(6):2465–2472. doi:10.7314/APJCP.2015.16.6.2465

    Article  PubMed  Google Scholar 

  18. Davey V, Robinson B, Dijkstra B, Harris G (2012) The Christchurch Breast Cancer Patient Register: the first year. N Z Med J 125(1360):37–47

    PubMed  Google Scholar 

  19. Seneviratne S, Lawrenson R, Scott N, Kim B, Shirley R, Campbell I (2015) Breast cancer biology and ethnic disparities in breast cancer mortality in New Zealand: a cohort study. PLoS ONE 10 (4). doi:10.1371/journal.pone.0123523

  20. Lawrenson R, Seneviratne S, Scott N, Peni T, Brown C, Campbell I (2016) Breast cancer inequities between Maori and non-Maori women in Aotearoa/New Zealand. Eur J Cancer Care 25(2):225–230. doi:10.1111/ecc.12473

    Article  CAS  Google Scholar 

  21. Seneviratne S, Campbell I, Scott N, Coles C, Lawrenson R (2015) Treatment delay for Māori women with breast cancer in New Zealand. Ethn Health 20(2):178–193. doi:10.1080/13557858.2014.895976

    Article  PubMed  Google Scholar 

  22. Seneviratne S, Scott N, Lawrenson R, Campbell I (2015) Ethnic, socio-demographic and socio-economic differences in surgical treatment of breast cancer in New Zealand. ANZ J Surg. doi:10.1111/ans.13011

    Google Scholar 

  23. Seneviratne S, Campbell I, Scott N, Shirley R, Peni T, Lawrenson R (2014) Accuracy and completeness of the New Zealand Cancer Registry for staging of invasive breast cancer. Cancer Epidemiol 38(5):638–644. doi:10.1016/j.canep.2014.06.008

    Article  PubMed  Google Scholar 

  24. Tin ST, Elwood JM, Lawrenson R, Campbell I, Harvey V, Seneviratne S (2016) Differences in breast cancer survival between public and private care in New Zealand: which factors contribute? PLoS ONE. doi:10.1371/journal.pone.0153206

  25. Sarfati D, Gurney J, Stanley J, Salmond C, Crampton P, Dennett E, Koea J, Pearce N (2014) Cancer-specific administrative data-based comorbidity indices provided valid alternative to Charlson and National Cancer Institute Indices. J Clin Epidemiol 67(5):586–595. doi:10.1016/j.jclinepi.2013.11.012

    Article  PubMed  Google Scholar 

  26. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22(8):1736–1747. doi:10.1093/annonc/mdr304

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL, Bellon JR, Wong JS, Smith BL, Harris JR (2011) Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol 29(29):3885–3891. doi:10.1200/JCO.2011.36.1105

    Article  PubMed  PubMed Central  Google Scholar 

  28. Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30(15):1796–1804. doi:10.1200/JCO.2011.38.8595

    Article  Google Scholar 

  29. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ (2009) Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. doi:10.1186/bcr2261

    PubMed  PubMed Central  Google Scholar 

  30. Huober J, Von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Högel B, Darb-Esfahani S, Mehta K, Loibl S (2010) Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat 124(1):133–140. doi:10.1007/s10549-010-1103-9

    Article  CAS  PubMed  Google Scholar 

  31. Seneviratne S, Campbell I, Scott N, Shirley R, Peni T, Lawrenson R (2015) Ethnic differences in breast cancer survival in New Zealand: contributions of differences in screening, treatment, tumor biology, demographics and comorbidities. Cancer Causes Control 26(12):1813–1824. doi:10.1007/s10552-015-0674-5

    Article  PubMed  Google Scholar 

  32. Seneviratne S, Lawrenson R, Harvey V, Ramsaroop R, Elwood M, Scott N, Sarfati D, Campbell I (2016) Stage of breast cancer at diagnosis in New Zealand: impacts of socio-demographic factors, breast cancer screening and biology. BMC Cancer 16 (1). doi:10.1186/s12885-016-2177-5

  33. Parise C, Caggiano V (2014) Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California. Cancer Epidemiol 38(5):556–562. doi:10.1016/j.canep.2014.08.001

    Article  PubMed  Google Scholar 

  34. Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, dos-Santos-Silva I, Ursin G (2017) Parity, hormones and breast cancer subtypes—results from a large nested case-control study in a national screening program. Breast Cancer Res 19(1). doi:10.1186/s13058-016-0798-x

  35. Agresti R, Meneghini E, Baili P, Minicozzi P, Turco A, Cavallo I, Funaro F, Amash H, Berrino F, Tagliabue E, Sant M (2016) Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study. Breast Cancer Res Treat 157(1):179–189. doi:10.1007/s10549-016-3802-3

    Article  CAS  PubMed  Google Scholar 

  36. Cerne JZ, Ferk P, Frkovic-Grazio S, Leskosek B, Gersak K (2012) Risk factors for HR- and HER2-defined breast cancer in Slovenian postmenopausal women. Climacteric 15(1):68–74. doi:10.3109/13697137.2011.609286

    Article  PubMed  Google Scholar 

  37. Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jönsson G, Olsson H, Borg Å, Ringnér M (2010) Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res. doi:10.1186/bcr2590

    Google Scholar 

  38. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, Adams-Campbell LL, Lane D, Stefanick ML, Vitolins M, Kabat GC, Rohan TE, Li CI (2011) Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 103(6):470–477. doi:10.1093/jnci/djr030

    Article  PubMed  PubMed Central  Google Scholar 

  39. Statistics New Zealand (2011) Demographic Trends: 2011. http://www.stats.govt.nz/browse_for_stats/population/estimates_and_projections/demographic-trends-2011/births.aspx. Accessed 11 September 2017

  40. Ministry of Health (2016) Annual update of key results 2015/16: New Zealand Health Survey. Ministry of Health, Wellington

    Google Scholar 

  41. Lawrenson R, Lao C, Campbell I, Harvey V, Brown C, Seneviratne S, Edwards M, Elwood M, Kuper-Hommel M (2017) The use of trastuzumab in New Zealand women with breast cancer. Asia Pac J Clin Oncol. doi:10.1111/ajco.12766

    PubMed  Google Scholar 

Download references

Acknowledgments

We would like to acknowledge the financial support from the Health Research Council of New Zealand, the Auckland and Waikato Breast Cancer Registers for providing the detailed data.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ross Lawrenson.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lawrenson, R., Lao, C., Campbell, I. et al. Treatment and survival disparities by ethnicity in New Zealand women with stage I–III breast cancer tumour subtypes. Cancer Causes Control 28, 1417–1427 (2017). https://doi.org/10.1007/s10552-017-0969-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-017-0969-9

Keywords

Navigation